ISO(ISO)
ISO
10/16/26
IsoPlexis (ISO)
Friday
3:45 PM
ThesisConcerns over liquidity and operational losses are overshadowing potential growth opportunities, leading to a more cautious outlook among investors.
Revenue Outlook
What Moves the Stock
- 01Adoption rates of IsoPlexis systems in research institutions and pharmaceutical companies
- 02Partnerships or collaborations with major biotech firms
- 03Regulatory approvals for new applications of its technology
- 04Market demand for single-cell analysis in drug development
- 05Sales of IsoPlexis systems - 70%
- 06Consumables and reagents - 20%
- 07Service and support - 10%
- 08Growth in personalized medicine and targeted therapies
FY2022 Snapshot
- Revenue
- $17M
- Rev. Growth
- -2.9%
- Gross Margin
- -5.5%
- Op. Margin
- -604%
- Net Margin
- -689%
- Net Income
- $-116M
- NI Growth
- -38.2%
- EPS
- $-2.94
ISO Chart
No chart data
My Notes
- "Management's recent comments indicate a need to reassess funding strategies amidst rising operational costs."
- Moat: IsoPlexis has a strong competitive advantage due to its proprietary technology and established relationships with key research institutions.
- growth - Investors seeking exposure to innovative healthcare technologies and potential high returns from market expansion.
- Higher interest rates could increase financing costs for expansion and R&D, potentially impacting growth plans and valuation multiples.
- Watch on earnings: Sales growth of IsoPlexis systems, Market share in single-cell analysis, Gross margin on consumables.
One Sentence Summary:
IsoPlexis: the story is balanced — adoption rates of isoplexis systems in research institutions and pharmaceutical companies.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
Explore More
Stock Comparison
Compare equities side by side
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Market Movers
Today's biggest gainers and losers
Market Heatmap
Visual sector performance
